CN102596946B - 抗病毒化合物及其制备和使用方法 - Google Patents
抗病毒化合物及其制备和使用方法 Download PDFInfo
- Publication number
- CN102596946B CN102596946B CN201080044361.6A CN201080044361A CN102596946B CN 102596946 B CN102596946 B CN 102596946B CN 201080044361 A CN201080044361 A CN 201080044361A CN 102596946 B CN102596946 B CN 102596946B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- nitro
- chloro
- methyl
- piperazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23143109P | 2009-08-05 | 2009-08-05 | |
| US61/231,431 | 2009-08-05 | ||
| PCT/CN2010/001187 WO2011015037A1 (en) | 2009-08-05 | 2010-08-05 | Antiviral compounds and methods of making and using there of cross reference to related applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102596946A CN102596946A (zh) | 2012-07-18 |
| CN102596946B true CN102596946B (zh) | 2015-06-17 |
Family
ID=43543887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080044361.6A Active CN102596946B (zh) | 2009-08-05 | 2010-08-05 | 抗病毒化合物及其制备和使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2462138B1 (enExample) |
| JP (1) | JP2013501008A (enExample) |
| KR (1) | KR20120092567A (enExample) |
| CN (1) | CN102596946B (enExample) |
| AU (1) | AU2010281265A1 (enExample) |
| BR (1) | BR112012002331A2 (enExample) |
| CA (1) | CA2770140A1 (enExample) |
| IL (1) | IL217745A0 (enExample) |
| IN (1) | IN2012DN01254A (enExample) |
| MX (1) | MX2012001504A (enExample) |
| RU (1) | RU2012104214A (enExample) |
| SG (1) | SG178106A1 (enExample) |
| WO (1) | WO2011015037A1 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0918249D0 (en) | 2009-10-19 | 2009-12-02 | Respivert Ltd | Compounds |
| WO2011147198A1 (en) * | 2010-05-28 | 2011-12-01 | Versitech Limited | Compounds and methods for treatment of proliferative diseases |
| CN103201268B (zh) * | 2010-09-08 | 2015-08-12 | 百时美施贵宝公司 | 作为广谱流感抗病毒药物的新型哌嗪类似物 |
| CN103209977A (zh) * | 2010-09-28 | 2013-07-17 | 百时美施贵宝公司 | 作为广谱抗流感病毒剂的带有取代的杂芳基的新的哌嗪类似物 |
| UY33337A (es) | 2010-10-18 | 2011-10-31 | Respivert Ltd | DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| WO2012134967A2 (en) * | 2011-03-25 | 2012-10-04 | Bristol-Myers Squibb Company | Three-dimensional structure of hin1 nucleoprotein in complex with antiviral compounds |
| KR101369584B1 (ko) * | 2011-04-19 | 2014-03-06 | 일양약품주식회사 | 페닐-이속사졸 유도체 및 그의 제조방법 |
| CN102432555A (zh) * | 2011-09-09 | 2012-05-02 | 中国科学院广州生物医药与健康研究院 | 1,2,3-三氮唑-4（5）羧酰胺类化合物及其应用 |
| TWI586378B (zh) | 2012-03-13 | 2017-06-11 | 瑞斯比維特有限公司 | 新穎醫藥調配物 |
| US9676734B2 (en) | 2012-05-18 | 2017-06-13 | Vironova Influenza Ab | Compounds and methods |
| EA029044B1 (ru) | 2012-05-18 | 2018-02-28 | Виронова Инфлуэнза Аб | Соединения метантиона, обладающие противовирусной активностью |
| UA125503C2 (uk) | 2012-06-13 | 2022-04-13 | Інсайт Холдинґс Корпорейшн | Заміщені трициклічні сполуки як інгібітори fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| AR095353A1 (es) | 2013-03-15 | 2015-10-07 | Respivert Ltd | Compuesto |
| JO3279B1 (ar) | 2013-03-15 | 2018-09-16 | Respivert Ltd | مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز |
| MY181497A (en) | 2013-04-19 | 2020-12-23 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| CA2914762C (en) * | 2013-07-30 | 2021-11-23 | Janssen Sciences Ireland Uc | Substituted pyridine-piperazinyl analogues as rsv antiviral compounds |
| GB201314452D0 (en) | 2013-08-13 | 2013-09-25 | Ostara Biomedical Ltd | Embryo implantation |
| GB201415569D0 (en) | 2014-09-03 | 2014-10-15 | C4X Discovery Ltd | Therapeutic Compounds |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| GB201501302D0 (en) | 2015-01-27 | 2015-03-11 | Ostara Biomedical Ltd | Embryo implantation |
| CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| GB201517523D0 (en) | 2015-10-05 | 2015-11-18 | Ostara Biomedical Ltd | Methods and compositions for managing reproduction |
| GB201601703D0 (en) | 2016-01-29 | 2016-03-16 | C4X Discovery Ltd | Therapeutic compounds |
| CN107056762B (zh) * | 2016-12-22 | 2020-08-28 | 四川百利药业有限责任公司 | 一种用作抗流感病毒的双羰基类似物 |
| US11040963B2 (en) | 2017-02-02 | 2021-06-22 | Janssen Vaccines & Prevention B.V. | Piperazine derivatives for influenza virus inhibitions |
| WO2018141854A1 (en) | 2017-02-02 | 2018-08-09 | Janssen Vaccines & Prevention B.V. | Piperazine derivatives for influenza virus inhibition |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| BR112020022392A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | formas sólidas de um inibidor de fgfr e processos para preparação das mesmas |
| PE20210919A1 (es) | 2018-05-04 | 2021-05-19 | Incyte Corp | Sales de un inhibidor de fgfr |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| DK3820573T3 (da) | 2018-07-10 | 2023-10-23 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme |
| MX2021008661A (es) | 2019-01-18 | 2021-08-19 | Astrazeneca Ab | Inhibidores de la pcsk9 y metodos de uso de los mismos. |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TWI765323B (zh) * | 2019-08-22 | 2022-05-21 | 大陸商四川海思科製藥有限公司 | 抗流感病毒化合物及其製備方法和用途 |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| GEP20247679B (en) | 2019-10-14 | 2024-10-10 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CN115135383B (zh) | 2020-02-18 | 2024-06-11 | 吉利德科学公司 | 抗病毒化合物 |
| TWI883391B (zh) | 2020-02-18 | 2025-05-11 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| WO2021204923A1 (en) | 2020-04-09 | 2021-10-14 | Vironova Medical Ab | Antiviral agents |
| WO2021204924A1 (en) | 2020-04-09 | 2021-10-14 | Vironova Medical Ab | Compounds for use in the treatment of hypercytokinemia |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| JP7688152B2 (ja) | 2021-04-16 | 2025-06-03 | ギリアード サイエンシーズ， インコーポレイテッド | アミドを使用してカルバヌクレオシドを調製する方法 |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| KR20240049311A (ko) | 2021-08-18 | 2024-04-16 | 길리애드 사이언시즈, 인코포레이티드 | 인지질 화합물 및 이의 제조 및 사용 방법 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004017971A1 (de) * | 2002-08-08 | 2004-03-04 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von papaverinartigem vasodilatator und pharmazeutische zusammensetzung |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05117150A (ja) * | 1991-10-25 | 1993-05-14 | Sanwa Kagaku Kenkyusho Co Ltd | 抗ウイルス剤 |
| KR200293242Y1 (ko) * | 2002-04-18 | 2002-11-01 | 전이범 | 산소 절단기호스 |
| AU2006214164B2 (en) * | 2005-02-17 | 2010-12-09 | Synta Pharmaceuticals Corp. | Isoxazole combretastin derivatives for the treatment of disorders |
| JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
-
2010
- 2010-08-05 IN IN1254DEN2012 patent/IN2012DN01254A/en unknown
- 2010-08-05 EP EP10805941.1A patent/EP2462138B1/en active Active
- 2010-08-05 WO PCT/CN2010/001187 patent/WO2011015037A1/en not_active Ceased
- 2010-08-05 CN CN201080044361.6A patent/CN102596946B/zh active Active
- 2010-08-05 MX MX2012001504A patent/MX2012001504A/es not_active Application Discontinuation
- 2010-08-05 CA CA2770140A patent/CA2770140A1/en not_active Abandoned
- 2010-08-05 SG SG2012005450A patent/SG178106A1/en unknown
- 2010-08-05 BR BR112012002331A patent/BR112012002331A2/pt not_active IP Right Cessation
- 2010-08-05 KR KR1020127005837A patent/KR20120092567A/ko not_active Withdrawn
- 2010-08-05 JP JP2012523184A patent/JP2013501008A/ja active Pending
- 2010-08-05 AU AU2010281265A patent/AU2010281265A1/en not_active Abandoned
- 2010-08-05 RU RU2012104214/04A patent/RU2012104214A/ru not_active Application Discontinuation
-
2012
- 2012-01-26 IL IL217745A patent/IL217745A0/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004017971A1 (de) * | 2002-08-08 | 2004-03-04 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von papaverinartigem vasodilatator und pharmazeutische zusammensetzung |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120092567A (ko) | 2012-08-21 |
| EP2462138A1 (en) | 2012-06-13 |
| AU2010281265A1 (en) | 2012-03-22 |
| WO2011015037A1 (en) | 2011-02-10 |
| CN102596946A (zh) | 2012-07-18 |
| IN2012DN01254A (enExample) | 2015-05-15 |
| JP2013501008A (ja) | 2013-01-10 |
| CA2770140A1 (en) | 2011-02-10 |
| MX2012001504A (es) | 2012-06-01 |
| EP2462138A4 (en) | 2013-01-23 |
| SG178106A1 (en) | 2012-03-29 |
| AU2010281265A2 (en) | 2012-04-05 |
| EP2462138B1 (en) | 2014-09-24 |
| BR112012002331A2 (pt) | 2019-09-24 |
| IL217745A0 (en) | 2012-03-29 |
| RU2012104214A (ru) | 2013-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102596946B (zh) | 抗病毒化合物及其制备和使用方法 | |
| US9212177B2 (en) | Antiviral compounds and methods of making and using thereof | |
| JP6804790B1 (ja) | Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 | |
| US20120149715A1 (en) | Compounds and methods for the treatment of viral infections | |
| TW201932113A (zh) | 經取代之多環性吡啶酮衍生物及含有其前體之醫藥組合物 | |
| JP5906244B2 (ja) | 哺乳類細胞中へのウイルスの侵入の阻害剤 | |
| CN109678715B (zh) | 2-(1-酰氧正戊基)苯甲酸与碱性氨基酸或氨基胍形成的盐、其制备方法及用途 | |
| CN105777464A (zh) | 异羟肟酸衍生物及其制备方法和应用 | |
| JP7655933B2 (ja) | 新規ハイドロキノン誘導体 | |
| CN113045550A (zh) | 一种三氮唑类衍生物及其制备方法和应用 | |
| US10450295B2 (en) | Method of using an indolinone molecule and derivatives for inhibiting liver fibrosis and hepatitis | |
| CN119320367B (zh) | 取代噁二唑-苯胺类化合物及其用途 | |
| CN117800916B (zh) | 1-[(1h-吲唑-7-基)甲基]-3-芳基硫脲衍生物的制备及其应用 | |
| CN115397466A (zh) | 新型3，5-二氨基苯甲酸系化合物和使用该化合物的Pin1抑制剂以及炎症性疾病的治疗剂 | |
| CN118063386B (zh) | (e)-n-[(1h-吲唑-7-基)甲基]-3-芳基丙烯酰胺衍生物的制备及其应用 | |
| EP1844775B1 (en) | Therapeutic agent for the treatment of herpes progenitalis after development of lesions | |
| CN1793120A (zh) | 具有抑制病毒衣壳蛋白活性的硫脲类新化合物、制备方法及用途 | |
| CN108129486A (zh) | 嘧啶酮衍生物及其用途 | |
| EP1844776B1 (en) | Agent for prevention/treatment of disease caused by acyclovir-resistant herpesvirus | |
| CN117586233A (zh) | N-[(1h-吲哚-4-基)烷基]苯甲酰胺类化合物的制备及其应用 | |
| CN114057635A (zh) | 2-芳脲基-n-[2-(2-甲氧基苯氧基)乙基]烟酰胺类化合物及其应用 | |
| CN113979936A (zh) | 2-芳脲基-n-[3-(4-吗啉基)丙基]烟酰胺类化合物及其应用 | |
| JP2006169176A (ja) | 抗コロナウイルス活性を有するインドリル−ペンテン−ジオン誘導体 | |
| CN113979935A (zh) | 2-芳脲基-n-(4-氟苄基)烟酰胺类化合物及其应用 | |
| JP2021535200A (ja) | 治療的介入のためのＨＩＶ−１ Ｎｅｆ−ＣＤ８０／ＣＤ８６相互作用を標的化する阻害剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |